Diet, exercise and a symbiotic supplement for early kidney disease in young people
Tests diet, exercise and a symbiotic supplement in young people with early kidney disease.
Plain-language title generated from the registry record
Registry title: Multimodal Intervention for Early Chronic Kidney Disease in Young People: Dysbiosis and Inflammation (CKD)
Key facts
- Where
- Aguascalientes, MexicoSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 35 years old?
Source: NCT07483697, who can take part
Where in Mexico
- Instituto de atención Integral de Enfermedades Renales del Estado de AguascalientesAguascalientes, MexicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centenario Hospital Miguel Hidalgo
- Trial code
- NCT07483697
- Record updated
- 19 March 2026
- Original description
Chronic kidney disease (CKD) is a progressive condition associated with substantial morbidity, mortality, and healthcare costs. Early detection and timely intervention are critical to modify disease trajectory, particularly in adolescents and young adults. Emerging evidence supports the role of the gut-kidney axis in CKD progression, whereby intestinal dysbiosis contributes to systemic inflammation and accumulation of microbiota-derived uremic toxins. This randomized controlled clinical trial aims to evaluate whether a multimodal intervention consisting of a controlled diet, structured exercise, and a symbiotic administered for 180 days improves uremic toxin burden, systemic inflammation, and early renal outcomes compared with standard care plus placebo.Read full original descriptionShow less
Multimodal Intervention and Its Association With Reduced Dysbiosis and Inflammation in Early Chronic Kidney Disease in Young People: a Prospective Study
Chronic kidney disease (CKD) is a progressive condition associated with substantial morbidity, mortality, and healthcare costs. Early detection and timely intervention are critical to modify disease trajectory, particularly in adolescents and young adults. Emerging evidence supports the role of the gut-kidney axis in CKD progression, whereby intestinal dysbiosis contributes to systemic inflammation and accumulation of microbiota-derived uremic toxins. This randomized controlled clinical trial aims to evaluate whether a multimodal intervention consisting of a controlled diet, structured exercise, and a symbiotic administered for 180 days improves uremic toxin burden, systemic inflammation, and early renal outcomes compared with standard care plus placebo.
Inclusion: Persistent albuminuria (ACR >30 and <300 mg/g); Estimated GFR >60 mL/min/1.73 m²; No identifiable secondary cause of kidney disease.
Exclusion: Nephrotic syndrome; Secondary or hereditary kidney disease; Hypoalbuminemia; Persistent macroalbuminuria (ACR >300 mg/g).